Title |
Sarcopenia in daily practice: assessment and management
|
---|---|
Published in |
BMC Geriatrics, October 2016
|
DOI | 10.1186/s12877-016-0349-4 |
Pubmed ID | |
Authors |
Charlotte Beaudart, Eugène McCloskey, Olivier Bruyère, Matteo Cesari, Yves Rolland, René Rizzoli, Islène Araujo de Carvalho, Jotheeswaran Amuthavalli Thiyagarajan, Ivan Bautmans, Marie-Claude Bertière, Maria Luisa Brandi, Nasser M. Al-Daghri, Nansa Burlet, Etienne Cavalier, Francesca Cerreta, Antonio Cherubini, Roger Fielding, Evelien Gielen, Francesco Landi, Jean Petermans, Jean-Yves Reginster, Marjolein Visser, John Kanis, Cyrus Cooper |
Abstract |
Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice. This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations. This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions. Development of a number of pharmacological interventions is also in progress. Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 6 | 18% |
United States | 4 | 12% |
Australia | 3 | 9% |
France | 2 | 6% |
Belgium | 2 | 6% |
Netherlands | 1 | 3% |
Ireland | 1 | 3% |
Unknown | 14 | 42% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 12 | 36% |
Members of the public | 12 | 36% |
Scientists | 8 | 24% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | <1% |
Germany | 1 | <1% |
Unknown | 1120 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 150 | 13% |
Student > Master | 126 | 11% |
Student > Ph. D. Student | 96 | 9% |
Researcher | 89 | 8% |
Student > Postgraduate | 72 | 6% |
Other | 209 | 19% |
Unknown | 380 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 334 | 30% |
Nursing and Health Professions | 141 | 13% |
Sports and Recreations | 63 | 6% |
Biochemistry, Genetics and Molecular Biology | 24 | 2% |
Agricultural and Biological Sciences | 18 | 2% |
Other | 114 | 10% |
Unknown | 428 | 38% |